



BMI CHART

Date: 8/9/20

Name: MR. Mohammed Nawala Age: 60 yrs

Sex: M/F

BP: 100/60 mmHg Height (cms): 159 cm Weight(kgs): 67.7 kg BMI: _____

SpO2 - 99.1
Pulse - 68 bpm

WEIGHT lbs	100	105	110	115	120	125	130	135	140	145	150	155	160	165	170	175	180	185	190	195	200	205	210	215				
kgs	45.5	47.7	50.0	52.3	54.5	56.8	59.1	61.4	63.6	65.9	68.2	70.5	72.7	75.0	77.3	79.5	81.8	84.1	86.4	88.6	90.9	93.2	95.5	97.7				
HEIGHT in/cm	Underweight	Healthy																								Overweight	Obese	Extremely Obese
5'0" - 152.4	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42				
5'1" - 154.9	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40					
5'2" - 157.4	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39						
5'3" - 160.0	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38						
5'4" - 162.5	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37							
5'5" - 165.1	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37						
5'6" - 167.6	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37						
5'7" - 170.1	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37					
5'8" - 172.7	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37					
5'9" - 176.2	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36					
5'10" - 177.8	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36					
5'11" - 180.3	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36					
6'0" - 182.8	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35					
6'1" - 185.4	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35					
6'2" - 187.9	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34					
6'3" - 190.5	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34					
6'4" - 193.0	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34					

Doctors Notes:

Signature



UHID	12696369	Date	08/09/2023		
Name	Mr. Mohammad Nasir Unawala	Sex	Male	Age	60
OPD	Dental 12 7387696540	Health Check-up			

O/E-

- Stains ++
 - calculus ++

- Grade III mobile +4

- Gen. chro m³ periodont. Hs.

Drug allergy:
 Sys illness:

H/O. Diabetes.
 6 years.
 cigarette smoking
 40 years.

Treatment:

② Adv. oral prophylaxis

③ Adv. Extraction +4

④ Adv. CBCT. (full mouth)

⑤ Adv. stop page of habit.

Dr. Anurag



UHID	12696369	Date	08/09/2023		
Name	Mr. Mohammad Nasir Unawala	Sex	Male	Age	60
OPD	Ophthal 14	Health Check-up			

CU - NO

Drug allergy: NO
 Sys illness: ver

H/O DM: 8 yrs

Habit → Smoking

Nr. 4/10 Spectacle usage

Unaided Vd T 6/6
6/6

Ref of Plane — 6/6

Meer Add T +2.50 DS
+2.50 DS

IOP T 15.2 mmHg
14.2

Am
 Prescribe Spec

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA
REF. DOCTOR :
CODE/NAME & ADDRESS : C000045507
 FORTIS VASHI-CHC -SPLZD
 FORTIS HOSPITAL # VASHI,
 MUMBAI 440001

ACCESSION NO : 0022WI001806
PATIENT ID : FH.12696387
CLIENT PATIENT ID: UID:12696387
ABHA NO :
AGE/SEX : 60 Years Male
DRAWN : 08/09/2023 09:19:00
RECEIVED : 08/09/2023 09:19:41
REPORTED : 08/09/2023 13:03:28
CLINICAL INFORMATION :

 UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-150123OPCR051645
 BILLNO-150123OPCR051645

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC
CBC-5, EDTA WHOLE BLOOD
BLOOD COUNTS, EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	15.7	13.0 - 17.0	g/dL
METHOD : SLS METHOD			
RED BLOOD CELL (RBC) COUNT	5.91 High	4.5 - 5.5	mil/ μ L
METHOD : HYDRODYNAMIC FOCUSING			
WHITE BLOOD CELL (WBC) COUNT	9.52	4.0 - 10.0	thou/ μ L
METHOD : FLUORESCENCE FLOW CYTOMETRY			
PLATELET COUNT	260	150 - 410	thou/ μ L
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION			

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	49.3	40.0 - 50.0	%
METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD			
MEAN CORPUSCULAR VOLUME (MCV)	83.4	83.0 - 101.0	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.6 Low	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC)	31.8	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	12.7	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER			
MENTZER INDEX	14.1		
METHOD : CALCULATED PARAMETER			
MEAN PLATELET VOLUME (MPV)	11.3 High	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			

WBC DIFFERENTIAL COUNT

Dr.Akshay Dhotre
 Consultant Pathologist

Page 1 Of 16




View Details



View Report

PERFORMED AT :

 Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222,022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -


Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA
REF. DOCTOR :
CODE/NAME & ADDRESS : C000045507

 FORTIS VASHI-CHC -SPLZD
 FORTIS HOSPITAL # VASHI,
 MUMBAI 440001

ACCESSION NO : 0022WI001806

 PATIENT ID : FH.12696387
 CLIENT PATIENT ID: UID:12696387
 ABHA NO :

AGE/SEX : 60 Years Male

 DRAWN : 08/09/2023 09:19:00
 RECEIVED : 08/09/2023 09:19:41
 REPORTED : 08/09/2023 13:03:28

CLINICAL INFORMATION :

 UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-150123OPCR051645
 BILLNO-150123OPCR051645

Test Report Status	Final	Results	Biological Reference Interval	Units
NEUTROPHILS		60	40.0 - 80.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
LYMPHOCYTES		26	20.0 - 40.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
MONOCYTES		8	2.0 - 10.0	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
EOSINOPHILS		6	1 - 6	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
BASOPHILS		0	0 - 2	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE NEUTROPHIL COUNT		5.71	2.0 - 7.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		2.48	1.0 - 3.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.76	0.2 - 1.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.57 High	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0 Low	0.02 - 0.10	thou/ μ L
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		2.3		
METHOD : CALCULATED				

MORPHOLOGY

RBC

METHOD : MICROSCOPIC EXAMINATION

WBC

METHOD : MICROSCOPIC EXAMINATION

PLATELETS

METHOD : MICROSCOPIC EXAMINATION

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC

NORMAL MORPHOLOGY

ADEQUATE


Dr. Akshay Dhotre
 Consultant Pathologist

Page 2 Of 16



View Details



View Report

PERFORMED AT :

 Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222, 022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -


Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA
REF. DOCTOR :
CODE/NAME & ADDRESS : C000045507

 FORTIS VASHI-CHC -SPLZD
 FORTIS HOSPITAL # VASHI,
 MUMBAI 440001

ACCESSION NO : 0022WI001806
PATIENT ID : FH.12696387
CLIENT PATIENT ID: UID:12696387
ABHA NO :
AGE/SEX : 60 Years Male
DRAWN : 08/09/2023 09:19:00
RECEIVED : 08/09/2023 09:19:41
REPORTED : 08/09/2023 13:03:28
CLINICAL INFORMATION :

UID:12696387 REQNO-1579418

CORP-OPD

BILLNO-150123OPCR051645

BILLNO-150123OPCR051645

Test Report Status	Results	Biological Reference Interval	Units
Final			

Interpretation(s)

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia (>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504)

This ratio element is a calculated parameter and out of NABL scope.


Dr.Akshay Dhotre
 Consultant Pathologist

Page 3 Of 16




View Details



View Report

PERFORMED AT :

 Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222,022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -



Patient Ref. No. 2200000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA
REF. DOCTOR :
CODE/NAME & ADDRESS : C000045507

 FORTIS VASHI-CHC -SPLZD
 FORTIS HOSPITAL # VASHI,
 MUMBAI 440001

ACCESSION NO : 0022WI001806
PATIENT ID : FH.12696387
CLIENT PATIENT ID: UID:12696387
ABHA NO :
AGE/SEX : 60 Years Male
DRAWN : 08/09/2023 09:19:00
RECEIVED : 08/09/2023 09:19:41
REPORTED : 08/09/2023 13:03:28
CLINICAL INFORMATION :

UID:12696387 REQNO-1579418

CORP-OPD

BILLNO-150123OPCR051645

BILLNO-150123OPCR051645

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY
ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD

E.S.R	02	0 - 14	mm at 1 hr
-------	----	--------	------------

METHOD : WESTEREGREN METHOD

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitis, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.



 Dr.Akshay Dhotre
 Consultant Pathologist

Page 4 Of 16



View Details



View Report

PERFORMED AT :

 Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222,022-49723322,
 CIN - U74099PB1995PLC045956
 Email : -


Patient Ref. No. 2200000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA
REF. DOCTOR :
CODE/NAME & ADDRESS : C000045507
 FORTIS VASHI-CHC -SPLZD
 FORTIS HOSPITAL # VASHI,
 MUMBAI 440001

ACCESSION NO : 0022WI001806
PATIENT ID : FH.12696387
CLIENT PATIENT ID: UID:12696387
ABHA NO :
AGE/SEX : 60 Years Male
DRAWN : 08/09/2023 09:19:00
RECEIVED : 08/09/2023 09:19:41
REPORTED : 08/09/2023 13:03:28

CLINICAL INFORMATION :

 UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-150123OPCR051645
 BILLNO-150123OPCR051645

Test Report Status	Results	Biological Reference Interval	Units
Final			

IMMUNOHAEMATOLOGY
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP	TYPE B
METHOD : TUBE AGGLUTINATION	
RH TYPE	POSITIVE
METHOD : TUBE AGGLUTINATION	

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.



Dr.Akshay Dhotre
 Consultant Pathologist

Page 5 Of 16



View Details



View Report

PERFORMED AT :

 Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222,022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -


Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA

REF. DOCTOR :

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001

ACCESSION NO : 0022WI001806
PATIENT ID : FH.12696387
CLIENT PATIENT ID: UID:12696387
ABHA NO :

AGE/SEX : 60 Years Male
DRAWN : 08/09/2023 09:19:00
RECEIVED : 08/09/2023 09:19:41
REPORTED : 08/09/2023 13:03:28

CLINICAL INFORMATION :

UID:12696387 REQNO-1579418
CORP-OPD
BILLNO-1501230PCR051645
BILLNO-1501230PCR051645

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.59	0.2 - 1.0	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT	0.17	0.0 - 0.2	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, INDIRECT	0.42	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.4	6.4 - 8.2	g/dL
METHOD : BIURET			
ALBUMIN	4.0	3.4 - 5.0	g/dL
METHOD : BCP DYE BINDING			
GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.2	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	26	15 - 37	U/L
METHOD : UV WITH PSP			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	50 High	< 45.0	U/L
METHOD : UV WITH PSP			
ALKALINE PHOSPHATASE	61	30 - 120	U/L
METHOD : PNPP-ANP			
GAMMA GLUTAMYL TRANSFERASE (GGT)	63	15 - 85	U/L
METHOD : GAMMA GLUTAMYL CARBOXY 4NITROANILIDE			
LACTATE DEHYDROGENASE	141	85 - 227	U/L
METHOD : LACTATE -PYRUVATE			

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)	282 High	Normal : < 100 Pre-diabetes: 100-125 Diabetes: >=126	mg/dL
---------------------------	----------	--	-------

METHOD : HEXOKINASE



Dr. Akshay Dhotre
Consultant Pathologist

Page 6 Of 16



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222, 022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA

REF. DOCTOR :

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001

ACCESSION NO : 0022WI001806

PATIENT ID : FH.12696387

CLIENT PATIENT ID: UID:12696387

ABHA NO :

AGE/SEX : 60 Years Male

DRAWN : 08/09/2023 09:19:00

RECEIVED : 08/09/2023 09:19:41

REPORTED : 08/09/2023 13:03:28

CLINICAL INFORMATION :

UID:12696387 REQNO-1579418
CORP-OPD
BILLNO-150123OPCR051645
BILLNO-150123OPCR051645

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C	9.5 High	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
-------	----------	--	---

METHOD : HB VARIANT (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG)	226.0 High	< 116.0	mg/dL
--------------------------------	------------	---------	-------

METHOD : CALCULATED PARAMETER

KIDNEY PANEL - 1**BLOOD UREA NITROGEN (BUN), SERUM**

BLOOD UREA NITROGEN	3 Low	8 - 23	mg/dL
---------------------	-------	--------	-------

METHOD : UREASE - UV

CREATININE EGFR- EPI

CREATININE	1.01	0.80 - 1.30	mg/dL
------------	------	-------------	-------

METHOD : ALKALINE PICRATE KINETIC JAFFES

AGE	60		years
-----	----	--	-------

GLOMERULAR FILTRATION RATE (MALE)	85.14	Refer Interpretation Below	mL/min/1.73m2
-----------------------------------	-------	----------------------------	---------------

METHOD : CALCULATED PARAMETER

BUN/CREAT RATIO

BUN/CREAT RATIO	2.97 Low	5.00 - 15.00	
-----------------	----------	--------------	--



Dr.Akshay Dhotre
Consultant Pathologist

Page 7 Of 16




View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222, 022-49723322,
CIN - U74899PB1995PLC045956
Email :-



Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA
REF. DOCTOR :
CODE/NAME & ADDRESS : C000045507
 FORTIS VASHI-CHC -SPLZD
 FORTIS HOSPITAL # VASHI,
 MUMBAI 440001

ACCESSION NO : 0022WI001806
PATIENT ID : FH.12696387
CLIENT PATIENT ID: UID:12696387
ABHA NO :
AGE/SEX : 60 Years Male
DRAWN : 08/09/2023 09:19:00
RECEIVED : 08/09/2023 09:19:41
REPORTED : 08/09/2023 13:03:28
CLINICAL INFORMATION :

 UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-150123OPCR051645
 BILLNO-150123OPCR051645

Test Report Status	Results	Biological Reference Interval	Units
--------------------	---------	-------------------------------	-------

METHOD : CALCULATED PARAMETER

URIC ACID, SERUM			
URIC ACID	0.7 Low	3.5 - 7.2	mg/dL
METHOD : URICASE UV			

TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.4	6.4 - 8.2	g/dL
METHOD : BIURET			

ALBUMIN, SERUM			
ALBUMIN	4.0	3.4 - 5.0	g/dL
METHOD : BCP DYE BINDING			

GLOBULIN			
GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			

ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	136	136 - 145	mmol/L
METHOD : ISE INDIRECT			
POTASSIUM, SERUM	3.75	3.50 - 5.10	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	100	98 - 107	mmol/L
METHOD : ISE INDIRECT			


Dr. Akshay Dhotre
 Consultant Pathologist

Page 8 Of 16



View Details



View Report

PERFORMED AT :

 Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222, 022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -


 Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA

REF. DOCTOR :

CODE/NAME & ADDRESS : C000045507
 FORTIS VASHI-CHC -SPLZD
 FORTIS HOSPITAL # VASHI,
 MUMBAI 440001

ACCESSION NO : 0022WI001806
PATIENT ID : FH.12696387
CLIENT PATIENT ID: UID:12696387
ABHA NO :

AGE/SEX : 60 Years Male
DRAWN : 08/09/2023 09:19:00
RECEIVED : 08/09/2023 09:19:41
REPORTED : 08/09/2023 13:03:28

CLINICAL INFORMATION :

UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-150123OPCR051645
 BILLNO-150123OPCR051645

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Interpretation(s)

Interpretation(s)

LIVER FUNCTION PROFILE, SERUM-
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.
AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.
ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.
GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.
Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.
Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.
GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION
 Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.
Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.
Decreased in: Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs- insulin, ethanol, propranolol, sulfonylureas, tolbutamide, and other oral hypoglycemic agents.
NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.
 High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.
GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.

Dr. Akshay Dhotre
 Consultant Pathologist




View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222, 022-49723322,
 CIN - U74899PB1995PLC045956
 Email :-



Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA

REF. DOCTOR :

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001

ACCESSION NO : 0022WI001806

PATIENT ID : FH.12696387

CLIENT PATIENT ID: UID:12696387

ABHA NO :

AGE/SEX :60 Years Male

DRAWN :08/09/2023 09:19:00

RECEIVED :08/09/2023 09:19:41

REPORTED :08/09/2023 13:03:28

CLINICAL INFORMATION :

UID:12696387 REQNO-1579418

CORP-OPD

BILLNO-150123OPCR051645

BILLNO-150123OPCR051645

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2. Vitamin C & E are reported to falsely lower test results (possibly by inhibiting glycation of hemoglobin).

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate platform (Bornate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE EGFR- EPI-- Kidney disease outcomes quality initiative (KDOQI) guidelines state that estimation of GFR is the best overall indices of the Kidney function.

- It gives a rough measure of number of functioning nephrons. Reduction in GFR implies progression of underlying disease.

- The GFR is a calculation based on serum creatinine test.


- Creatinine is mainly derived from the metabolism of creatine in muscle, and its generation is proportional to the total muscle mass. As a result, mean creatinine generation is higher in men than in women, in younger than in older individuals, and in blacks than in whites.

- Creatinine is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate.

- When kidney function is compromised, excretion of creatinine decreases with a consequent increase in blood creatinine levels. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

- This equation takes into account several factors that impact creatinine production, including age, gender, and race.

- CKD EPI (Chronic kidney disease epidemiology collaboration) equation performed better than MDRD equation especially when GFR is high (>60 ml/min per 1.73m2).. This formula has less bias and greater accuracy which helps in early diagnosis and also reduces the rate of false positive diagnosis of CKD.


Dr. Akshay Dhotre
Consultant Pathologist

Page 10 Of 16




View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222, 022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 2200000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA		REF. DOCTOR :	
CODE/NAME & ADDRESS : C000045507 FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001	ACCESSION NO : 0022WI001806 PATIENT ID : FH.12696387 CLIENT PATIENT ID: UID:12696387 ABHA NO :	AGE/SEX : 60 Years Male DRAWN : 08/09/2023 09:19:00 RECEIVED : 08/09/2023 09:19:41 REPORTED : 08/09/2023 13:03:28	

CLINICAL INFORMATION :
 UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-150123OPCR051645
 BILLNO-150123OPCR051645

Test Report Status	Results	Biological Reference Interval	Units
Final			

BIOCHEMISTRY - LIPID

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL	94	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE			
TRIGLYCERIDES	196 High	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : ENZYMATIC ASSAY			
HDL CHOLESTEROL	32 Low	< 40 Low >/=60 High	mg/dL
METHOD : DIRECT MEASURE - PEG			
LDL CHOLESTEROL, DIRECT	44	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
METHOD : DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT			
NON HDL CHOLESTEROL	62	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD : CALCULATED PARAMETER			
VERY LOW DENSITY LIPOPROTEIN	39.2 High	</= 30.0	mg/dL
METHOD : CALCULATED PARAMETER			
CHOL/HDL RATIO	2.9 Low	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
METHOD : CALCULATED PARAMETER			

Dr. Akshay Dhotre
 Consultant Pathologist



View Details



View Report

PERFORMED AT :
 Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222, 022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -

Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA
REF. DOCTOR :
CODE/NAME & ADDRESS : C000045507
ACCESSION NO : 0022WI001806
AGE/SEX : 60 Years Male
**FORTIS VASHI-CHC -SPLZD
FORTIS HOSPITAL # VASHI,
MUMBAI 440001**
PATIENT ID : FH.12696387
DRAWN : 08/09/2023 09:19:00
CLIENT PATIENT ID: UID:12696387
RECEIVED : 08/09/2023 09:19:41
ABHA NO :
REPORTED : 08/09/2023 13:03:28
CLINICAL INFORMATION :
**UID:12696387 REQNO-1579418
CORP-OPD
BILLNO-150123OPCR051645
BILLNO-150123OPCR051645**

Test Report Status	Results	Biological Reference Interval	Units
Final	1.4	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

METHOD : CALCULATED PARAMETER
Interpretation(s)

**Dr.Akshay Dhotre
Consultant Pathologist**

Page 12 Of 16



View Details



View Report

PERFORMED AT :
**Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email : -**

Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA		REF. DOCTOR :	
CODE/NAME & ADDRESS : C000045507	ACCESSION NO : 0022WI001806	AGE/SEX : 60 Years Male	DRAWN : 08/09/2023 09:19:00
FORTIS VASHI-CHC -SPLZD	PATIENT ID : FH.12696387	RECEIVED : 08/09/2023 09:19:41	REPORTED : 08/09/2023 13:03:28
FORTIS HOSPITAL # VASHI,	CLIENT PATIENT ID: UID:12696387		
MUMBAI 440001	ABHA NO :		

CLINICAL INFORMATION :
 UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-150123OPCR051645
 BILLNO-150123OPCR051645

Test Report Status	Results	Biological Reference Interval	Units
Final			

CLINICAL PATH - URINALYSIS

KIDNEY PANEL - 1

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW
APPEARANCE SLIGHTLY HAZY
 METHOD : PHYSICAL
 METHOD : VISUAL

CHEMICAL EXAMINATION, URINE

PH	6.0	4.7 - 7.5
METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD		
SPECIFIC GRAVITY	>=1.030	1.003 - 1.035
METHOD : REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)		
PROTEIN	DETECTED (++)	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE		
GLUCOSE	DETECTED (+++)	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD		
KETONES	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE		
BLOOD	DETECTED (+) IN URINE	
METHOD : REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN		
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT		
UROBILINOGEN	NORMAL	NORMAL
METHOD : REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRlich REACTION)		
NITRITE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED
METHOD : REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY		

Dr. Akta Dubey
 Consultant Pathologist

Dr. Rekha Nair, MD
 Microbiologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222,022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -



Patient Ref. No. 2200000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA		REF. DOCTOR :	
CODE/NAME & ADDRESS : C000045507	ACCESSION NO : 0022WI001806	AGE/SEX : 60 Years Male	
FORTIS VASHI-CHC -SPLZD	PATIENT ID : FH.12696387	DRAWN : 08/09/2023 09:19:00	
FORTIS HOSPITAL # VASHI,	CLIENT PATIENT ID: UID:12696387	RECEIVED : 08/09/2023 09:19:41	
MUMBAI 440001	ABHA NO :	REPORTED : 08/09/2023 13:03:28	

CLINICAL INFORMATION :

UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-150123OPCR051645
 BILLNO-150123OPCR051645

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS METHOD : MICROSCOPIC EXAMINATION	2 - 3	NOT DETECTED	/HPF
PUS CELL (WBC'S) METHOD : MICROSCOPIC EXAMINATION	5-7	0-5	/HPF
EPITHELIAL CELLS METHOD : MICROSCOPIC EXAMINATION	2-3	0-5	/HPF
CASTS METHOD : MICROSCOPIC EXAMINATION	GRANULAR CAST DETECTED +		
CRYSTALS METHOD : MICROSCOPIC EXAMINATION	CALCIUM OXALATE DETECTED +		
BACTERIA METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	
YEAST METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	
REMARKS	URINARY MICROSCOPIC EXAMINATION DONE ON URINARY CENTRIFUGED SEDIMENT.		

Interpretation(s)

Dr. Akta Dubey
 Consultant Pathologist

Dr. Rekha Nair, MD
 Microbiologist




View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222, 022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -



Patient Ref. No. 22000000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA
REF. DOCTOR :
CODE/NAME & ADDRESS : C000045507

 FORTIS VASHI-CHC -SPLZD
 FORTIS HOSPITAL # VASHI,
 MUMBAI 440001

ACCESSION NO : 0022WI001806
PATIENT ID : FH.12696387
CLIENT PATIENT ID: UID:12696387
ABHA NO :
AGE/SEX : 60 Years Male
DRAWN : 08/09/2023 09:19:00
RECEIVED : 08/09/2023 09:19:41
REPORTED : 08/09/2023 13:03:28
CLINICAL INFORMATION :

 UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-1501230PCR051645
 BILLNO-1501230PCR051645

Test Report Status	Results	Biological Reference Interval	Units
--------------------	---------	-------------------------------	-------

Final
SPECIALISED CHEMISTRY - HORMONE
THYROID PANEL, SERUM

T3	169.4	80.0 - 200.0	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE			
T4	9.14	5.10 - 14.10	µg/dL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE			
TSH (ULTRASENSITIVE)	4.080	0.270 - 4.200	µIU/mL
METHOD : ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY			

Interpretation(s)

Dr.Akta Dubey
 Counsultant Pathologist


View Details



View Report

PERFORMED AT :

 Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222,022-49723322,
 CIN - U74899PB1995PLC045956
 Email : -


Patient Ref. No. 2200000871073



PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA		REF. DOCTOR :	
CODE/NAME & ADDRESS : C000045507		ACCESSION NO : 0022WI001806	AGE/SEX : 60 Years Male
FORTIS VASHI-CHC -SPLZD		PATIENT ID : FH.12696387	DRAWN : 08/09/2023 09:19:00
FORTIS HOSPITAL # VASHI,		CLIENT PATIENT ID: UID:12696387	RECEIVED : 08/09/2023 09:19:41
MUMBAI 440001		ABHA NO :	REPORTED : 08/09/2023 13:03:28

CLINICAL INFORMATION :
 UID:12696387 REQNO-1579418
 CORP-OPD
 BILLNO-150123OPCR051645
 BILLNO-150123OPCR051645

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - TUMOR MARKER

PROSTATE SPECIFIC ANTIGEN, SERUM				ng/mL
PROSTATE SPECIFIC ANTIGEN	0.719	0.0 - 4.1		
METHOD : ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY				

Interpretation(s)
 PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis.
 - PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the female patients.
 - It is a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.
 - Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in detecting residual disease and early recurrence of tumor.
 - Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.
 - Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA (false positive) levels persisting up to 3 weeks.
 - As per American urological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific reference range can be used as a guide lines.
 - Measurement of total PSA alone may not clearly distinguish between benign prostatic hyperplasia (BPH) from cancer, this is especially true for the total PSA values between 4-10 ng/mL.
 - Total PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations. Recommended follow up on same platform as patient result can vary due to differences in assay method and reagent specificity.

- References-**
 1. Burtis CA, Ashwood ER, Bruns DE, Teltz textbook of clinical chemistry and Molecular Diagnostics. 4th edition.
 2. Williamson MA, Snyder LM. Wallach's interpretation of diagnostic tests. 9th edition.

****End Of Report****
 Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Akshay Dhotre
 Consultant Pathologist




View Details



View Report

PERFORMED AT :
 Agilus Diagnostics Ltd.
 Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
 Navi Mumbai, 400703
 Maharashtra, India
 Tel : 022-39199222, 022-49723322,
 CIN - U74899PB1995PLC045956
 Email :



Patient Ref. No. 2200000871073

PATIENT NAME : MR.MOHAMMAD NASIR UNAWALA		REF. DOCTOR :	
CODE/NAME & ADDRESS : C000045507		AGE/SEX : 60 Years Male	
FORTIS VASHI-CHC -SPLZD		DRAWN : 08/09/2023 11:53:00	
FORTIS HOSPITAL # VASHI,		RECEIVED : 08/09/2023 11:53:44	
MUMBAI 440001		REPORTED : 08/09/2023 12:42:00	
ACCESSION NO : 0022WI001851		PATIENT ID : FH.12696387	
CLIENT PATIENT ID: UID:12696387		ABHA NO :	

CLINICAL INFORMATION :

UID:12696387 REQNO-1579418
CORP-OPD
BILLNO-150123OPCR051645
BILLNO-150123OPCR051645

Test Report Status	Results	Biological Reference Interval	Units
Final			

BIOCHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA	Results	Biological Reference Interval	Units
PPBS(POST PRANDIAL BLOOD SUGAR)	411 High	70 - 140	mg/dL
METHOD : HEXOKINASE			

Interpretation(s)

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c

****End Of Report****

Please visit www.agilusdiagnostics.com for related Test Information for this accession



Dr. Akshay Dhotre
Consultant Pathologist



View Details



View Report

Page 1 Of 1

PERFORMED AT :

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel : 022-39199222, 022-49723322,
CIN - U74899PB1995PLC045956
Email : -



Patient Ref. No. 22000000871118

Hiranandani Healthcare Pvt. Ltd.
 Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.
 Board Line: 022 - 39199222 | Fax: 022 - 39133220
 Emergency: 022 - 39199100 | Ambulance: 1255
 For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300
 www.fortishealthcare.com | vashi@fortishealthcare.com
 CIN: U85100MH2005PTC 154823
 GST IN : 27AABCH5894D1ZG
 PAN NO : AABCH5894D



Date: 09/Sep/2023

DEPARTMENT OF NIC

Name: Mr. Mohammad Nasir Unawala
 Age | Sex: 60 YEAR(S) | Male
 Order Station : FO-OPD
 Bed Name :

UHID | Episode No : 12696387 | 52287/23/1501
 Order No | Order Date: 1501/PN/OP/2309/109074 | 08-Sep-2023
 Admitted On | Reporting Date : 09-Sep-2023 13:13:34
 Order Doctor Name : Dr.SELF .

ECHOCARDIOGRAPHY TRANSTHORACIC

FINDINGS: IHD S/P PTCA .

- Ischemic heart disease.
- Left ventricle entire anterior septum, entire anterior wall, entire inferior septum , apical lateral wall ,apical inferior wall and apical cap are severely hypokinetic with mild thinning of wall . Rest of the left ventricle wall shows normal contractility.
- Severely depressed left ventricle systolic function. LVEF approximately: 25-30%.
- Grade I left ventricle diastolic dysfunction. No e/o raised LVEDP.
- Mild mitral regurgitation.
- Mild aortic regurgitation. No aortic stenosis.
- Trivial tricuspid regurgitation. No pulmonary hypertension.
PASP = 25mmHg
- IAS and IVS are intact. Dilated left ventricle
- No left ventricle clots/vegetation/ pericardial effusion.
- Normal right atrium and right ventricle dimension.
- Normal right ventricle systolic function.
- IVC measures 15 mm with normal inspiratory collapse .

M-MODE MEASUREMENTS:

LA	31	mm
AO Root	23	mm
AO CUSP SEP	15	mm
LVID (s)	41	mm
LVID (d)	60	mm
IVS (d)	05	mm
LVPW (d)	08	mm
RVID (d)	29	mm
RA	31	mm
LVEF	25-30	%

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823

GST IN : 27AABCH5894D1ZG

PAN NO : AABCH5894D



Date: 09/Sep/2023

DEPARTMENT OF NIC

Name: Mr. Mohammad Nasir Unawala

Age | Sex: 60 YEAR(S) | Male

Order Station : FO-OPD

Bed Name :

UHID | Episode No : 12696387 | 52287/23/1501

Order No | Order Date: 1501/PN/OP/2309/109074 | 08-Sep-2023

Admitted On | Reporting Date : 09-Sep-2023 13:13:34

Order Doctor Name : Dr.SELF .

DOPPLER STUDY:

E WAVE VELOCITY: 0.8 m/sec.


A WAVE VELOCITY: 0.3 m/sec

E/A RATIO: 2.6 , E/E' = 24

	PEAK (mmHg)	MEAN (mmHg)	V max (m/sec)	GRADE OF REGURGITATION
MITRAL VALVE	N			Mild
AORTIC VALVE	09			Mild
TRICUSPID VALVE	25			Trivial
PULMONARY VALVE	04			Nil

Final Impression :

- IHD with severe LV systolic dysfunction.
- RWMA as above.
- Mild AR & MR .
- Trivial TR . No PH
- Grade II LV diastolic dysfunction.


DR. PRASHANT PAWAR
 DNB (MED), DNB (CARDIOLOGY)

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823

GST IN : 27AABCH5894D1ZG

PAN NO : AABCH5894D



Date: 08/Sep/2023

DEPARTMENT OF RADIOLOGY

Name: Mr. Mohammad Nasir Unawala

Age | Sex: 60 YEAR(S) | Male

Order Station : FO-OPD

Bed Name :

UHID | Episode No : 12696387 | 52287/23/1501

Order No | Order Date: 1501/PN/OP/2309/109074 | 08-Sep-2023

Admitted On | Reporting Date : 08-Sep-2023 11:37:40

Order Doctor Name : Dr.SELF .

X-RAY-CHEST- PA

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax is unremarkable.

DR. YOGINI SHAH
DMRD., DNB. (Radiologist)



(For Billing/Reports & Discharge Summary only)

Patient Name	: Mohammad Nasir Unawala	Patient ID	: 12696387
Sex / Age	: M / 60Y 5D	Accession No.	: PHC.6545296
Modality	: US	Scan DateTime	: 08-09-2023 10:05:28
IPID No	: 52287/23/1501	ReportDatetime	: 08-09-2023 10:19:32

USG – WHOLE ABDOMEN

LIVER is normal in size and shows raised echogenicity. No IHBR dilatation. No focal lesion is seen in liver. Portal vein appears normal in caliber.

GALL BLADDER is physiologically distended. Gall bladder reveals normal wall thickness. No evidence of calculi in gall bladder. No evidence of pericholecystic collection.
CBD appears normal in caliber.

SPLEEN is normal in size and echogenicity.

BOTH KIDNEYS are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.
Right kidney measures 10.4 x 3.9 cm.
Left kidney measures 10.8 x 4.3 cm.


PANCREAS is normal in size and morphology. No evidence of peripancreatic collection.

URINARY BLADDER is empty, limiting evaluation of pelvis.

PROSTATE is borderline enlarged in size & normal in echogenicity. It measures ~ 25.8 cc in volume.
No evidence of ascites.

Impression:

- Borderline prostatomegaly.


DR. CHETAN KHADKE
M.D. (Radiologist)